A practical reference on GHS-R1a: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-18 and is reviewed periodically as new material appears.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Contains two non-natural residues |
| Molecular formula | C38H49N9O5 | Free base form |
| Molecular weight | 711.85 g/mol | Calculated from formula |
| Primary target | GHS-R1a ghrelin receptor | Agonist activity |
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
The lyophilised solid is normally held at -20 °C or colder, shielded from light and moisture. Stability in that state is measured in years, although shelf life depends on residual water content and the container seal. Once dissolved, the peptide is more fragile: aqueous solutions are commonly kept at 2-8 °C and used within days to weeks, and repeated freeze-thaw cycling is avoided. Strongly acidic or basic conditions accelerate hydrolysis, and prolonged exposure to them can strip the terminal amide.
Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
=== Continuous-flow fast atom bombardment === CE can be coupled to fast atom bombardment ionization using a continuous flow interface. The interface must match the flow rate between the two systems. The CF-FAB requires a relatively high flow rate but CE need low flow rate for better separation. A make-up flow can be used using a sheath flow or liquid junction.
Myristicin poisoning can be detected by testing levels of myristicin in the blood. There are no known antidotes for myristicin poisoning, and treatment focuses on symptom management and potential sedation in cases of extreme delirium or aggravation.
== Controversy == In 2020, Horsley was involved in a Twitter feud. In 2021, Horsley had a dispute with fellow Hamden councilmember Justin Farmer, when she asked that he address her as "doctor", which was requested by the Hamden Council President a few months earlier in solidarity with Jill Biden. Her resignation was requested but Horsley finished her term. Despite this political opposition, Horsley has actively supported diversity in science as a founding co-Chair of Society of Investigative Dermatology's Diversity Committee.
Moreover, the ability to perform high frequency fractionation immediately from the eluent of a nano-LC column has greatly increases peak resolution and improved the overall separation quality when compared to continuous flow nano-LC devices. An HPLC column was first built directly into a microfluidic device by using TPE instead of PDMS for the device fabrication. The additional strength of TPE made it capable of supporting the higher pressures needed for HPLC such that a single, microfluidic lab-chip could perform chemical separation, fractionation, and further droplet manipulation. In order to increase the quality of chromatographic output, sturdier devices made of glass have shown the ability to withstand far greater pressure than TPE. Achieving these higher pressures to increase the degree of separation and eliminating all dead volumes through immediate droplet formation has shown the potential for droplet microfluidics to expand and improve the capabilities of HPLC separations.
Sources: en.wikipedia.org
==== Urquía Carreño sends restitution payments ==== In August, 2025, government agents from the Ministry of Justice showed up at the National Masonic Temple with some bankers, and delivered 1 million Cuban pesos to the Grand Lodge. They informed the Grand Lodge that this money had been discovered during the course of the police investigation into Urquía Carreño, and that they should expect 3 million more pesos soon after. Filema Duarte and the office of the Grand Master published Special Circular No. 127, in which they asserted that the accountant Gertrudis Mena had digitally manipulated and falsified bank statements to steal and embezzle large sums of money, of which former Grand Master Urquía Carreño had been an accomplice. The total volume of embezzlement, not including the theft of the Llansó fund, was valued at around US$40,000. While many Freemasons praised the justice system for prosecuting against Urquía Carreño, they also stated that they believed it was just a tactic used by Filema Duarte as a method of distraction from his own scandal. In September 2025, a second payment was received by the Grand Lodge of Cuba from Former Grand Master Urquía Carreño and Former Grand Treasurer Airam Cervera Reigosa, totaling 4 million Cuban pesos. Grand Master Filema Duarte announced that the total sum of 5 million pesos was deposited into the account of the Grand Lodge of Cuba. Technically, both deposits were made under the name Airam Cervera, but it was taken implicitly that this was repayment for what both men owed the Grand Lodge.
=== Small molecule inhibitors === Small molecules that are able to inhibit TGF-β induced EMT are under development. Silmitasertib (CX-4945) is a small molecule inhibitor of protein kinase CK2, which has been supported to be linked with TGF-β induced EMT, and is currently in clinical trials for cholangiocarcinoma (bile duct cancer), as well as in preclinical development for hematological and lymphoid malignancies. In January 2017, Silmitasertib was granted orphan drug status by the U.S. Food and Drug Administration for cholangiocarcinoma and is currently in phase II study. Silmitasertib is being developed by Senhwa Biosciences. Another small molecule inhibitor Galunisertib (LY2157299) is a potent TGF-β type I receptor kinase inhibitor that was demonstrated to reduce the size, the growth rate of tumors, and the tumor forming potential in triple negative breast cancer cell lines using mouse xenografts. Galunisertib is currently being developed by Lilly Oncology and is in phase I/II clinical trials for hepatocellular carcinoma, unresectable pancreatic cancer, and malignant glioma. Small molecule inhibitors of EMT are suggested to not act as a replacement for traditional chemotherapeutic agents but are likely to display the greatest efficacy in treating cancers when used in conjunction with them. Antagomirs and microRNA mimics have gained interest as a potential source of therapeutics to target EMT induced metastasis in cancer as well as treating many other diseases.
== History == Polymers have been essential components of commodities since the early days of humankind. The use of wool (keratin), cotton and linen fibres (cellulose) for garments, paper reed (cellulose) for paper are just a few examples of how ancient societies exploited polymer-containing raw materials to obtain artefacts. The latex sap of "caoutchouc" trees (natural rubber) reached Europe in the 16th century from South America long after the Olmec, Maya and Aztec had started using it as a material to make balls, waterproof textiles and containers. The chemical manipulation of polymers dates back to the 19th century, although at the time the nature of these species was not understood. The behaviour of polymers was initially rationalised according to the theory proposed by Thomas Graham which considered them as colloidal aggregates of small molecules held together by unknown forces. Notwithstanding the lack of theoretical knowledge, the potential of polymers to provide innovative, accessible and cheap materials was immediately grasped. The work carried out by Braconnot, Parkes, Ludersdorf, Hayward and many others on the modification of natural polymers determined many significant advances in the field. Their contributions led to the discovery of materials such as celluloid, galalith, parkesine, rayon, vulcanised rubber and, later, Bakelite: all materials that quickly entered industrial manufacturing processes and reached households as garments components (e.g., fabrics, buttons), crockery and decorative items.
GSH + R• → RH + GS• → 1/2 GSSG Thiyl radicals (such as glutathionyl radicals) are themselves oxidizing species in biology, with a single-electron reduction potential sufficient for oxidation of nucleic acids, proteins and polyunsaturated lipids. Therefore, GSH itself may not be effective at direct reduction of reactive oxygen species under physiological conditions. Under oxidizing conditions, hydrogen sulfide may react with glutathione (or other electrophilic oxidized forms of glutathione) to form glutathione hydropersulfide (GS–SH), which is a superior radical-trapping antioxidant and reductant. GSH is a highly important indirect antioxidant by acting as a coenzyme for various enzymes that couple GSH-to-GSSG oxidation to the reduction of harmful oxidizing species. Such enzymes include the glutathione peroxidase family, the glutaredoxin family, the peroxiredoxin family, and others.
==== TP0751 ==== The TP0751 protein is a protein that is unique to T. pallidum, and it is thought to aid in attachment to the host's extra cellular membrane. Since this protein aids in the attachment to the host, it sits on the surface of the cells, and in 2005, it was discovered that the TP0751 protein will attach to the laminin component in the host's extracellular matrix. With that, it is thought that the TP0751 protein plays a key role in dissemination with the host.
Sources: en.wikipedia.org
Gish's debating opponents said that he used a rapid-fire approach during a debate, presenting arguments and changing topics quickly. Eugenie Scott, executive director of the National Center for Science Education, dubbed this approach the "Gish gallop", describing it as "where the creationist is allowed to run on for 45 minutes or an hour, spewing forth torrents of error that the evolutionist hasn't a prayer of refuting in the format of a debate". She also criticized Gish for failing to answer objections raised by his opponents. However, Gish said a similar thing about his debate opponents, especially Kenneth Miller. Gish accused Miller of using spread debating, i.e. speaking very fast and bringing up so many points that there was no chance to answer them all. Gish was also criticized for using a standardized presentation during debates. While undertaking research for a debate with Gish, Michael Shermer noted that Gish re-used similar openings, assumptions about his opponent, slides, and even jokes. For example, during the debate, Gish attempted to prove that Shermer was indeed an atheist and therefore immoral, even though Shermer said he was not an atheist and was willing to accept the existence of a divine creator. Massimo Pigliucci, who debated Gish five times, said that Gish ignored evidence contrary to his religious beliefs. Robert Schadewald accused Gish of stonewalling arguments with fabricated data.
== Society and culture == Paroxetine was approved for medical use in the United States in 1992 and initially sold by GlaxoSmithKline. It is available as a generic medication. In 2022, it was the 92nd most commonly prescribed medication in the United States, with more than 7 million prescriptions. It is on the World Health Organization's List of Essential Medicines. GlaxoSmithKline has paid substantial fines, paid settlements in class-action lawsuits, and become the subject of several highly critical books about its marketing of paroxetine, in particular, the off-label marketing of paroxetine for children, the suppression of negative research results relating to its use in children, and allegations that it failed to warn consumers of substantial withdrawal effects associated with the use of the drug.
== Chemical properties == Temozolomide is an imidazotetrazine derivative. It is slightly soluble in water and aqueous acids, and decomposes at 212 °C (414 °F). It was discovered in 2021 that temozolomide is an explosive, tentatively assigned as UN Class 1. Temozolomide has also been reported to be a comparatively safe and stable in situ source of diazomethane in organic synthesis. In particular, use as a methylating and cyclopropanating reagent has been demonstrated.
To overcome the dust issues and poor flowability of the powder, a new generation of spray dryers called multiple effect spray dryers have been developed. Instead of drying the liquid in one stage, drying is done through two steps: the first at the top (as per single effect) and the second with an integrated static bed at the bottom of the chamber. The bed provides a humid environment which causes smaller particles to clump, producing more uniform particle sizes, usually within the range of 100 to 300 μm. These powders are free-flowing due to the larger particle size. The fine powders generated by the first stage drying can be recycled in continuous flow either at the top of the chamber (around the sprayed liquid) or at the bottom, inside the integrated fluidized bed. The drying of the powder can be finalized on an external vibrating fluidized bed. The hot drying gas can be passed in as a co-current, same direction as sprayed liquid atomizer, or counter-current, where the hot air flows against the flow from the atomizer. With co-current flow, particles spend less time in the system and the particle separator (typically a cyclone device). With counter-current flow, particles spend more time in the system and is usually paired with a fluidized bed system. Co-current flow generally allows the system to operate more efficiently. Alternatives to spray dryers are:
==== Polymers ==== Electronic components that require clear transparency for light to exit or enter (photovoltaic panels and sensors) can be potted using acrylic resins that are cured using UV energy. The advantages are low VOC emissions and rapid curing.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.
It acts as an agonist at the growth hormone secretagogue receptor, also known as the ghrelin receptor. Binding at pituitary somatotroph cells promotes growth hormone release.
Early studies report weaker effects on cortisol, prolactin, and appetite than compounds such as GHRP-6. The size of that difference in humans is not firmly established.
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.